Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - Priority Announcement: Breast Cancer

McMaster University

$100,000.00

Identification and characterization of drugs affecting serotonin signalling that may be repurposed to treat breast cancer

FY 2013-14

Summary
We have discovered that drugs commonly used to treat patients suffering from depression, anxiety or migraine headaches, block the growth of breast tumour cells. These drugs, which include Prozac, Paxil and Zoloft, affect serotonin levels in particular neurons in the brain that control mood. Of relevance to this proposal, studies have shown that serotonin acts in women after breastfeeding is halted, by ridding the breast of cells that secrete milk proteins, a process termed involution. Interestingly the machinery needed to make and respond to serotonin is present in both milk-secreting normal breast cells as well as in breast tumour cells. Our interest in the role of serotonin in breast cancer resulted from a screen for drugs that kill breast tumour cells. We found that roughly 25% of the active drugs were psycho-stimulants and antidepressants that block the activity of various neurotransmitters, including serotonin. Follow-up experiments showed that these drugs killed a subset of breast tumour cells, termed cancer stem cells or breast tumour initiating cells, which have been implicated in sustaining tumour growth, seeding metastases and providing resistance to anticancer therapies. We have accumulated a significant body of data demonstrating that drugs inhibiting distinct serotonin pathway components all reduce the frequency of breast cancer stem cells. Most, but not all, of our experiments employed tumour cells from mouse models of breast cancer. Our proposal centers on learning whether serotonergic drugs eradicate human breast cancer stem cells from breast tumours. The use of such drugs in combination with chemotherapy is predicted to lead to durable breast cancer remissions. Because many approved antidepressant drugs are chronically used to treat patients with mood disorders the prospects are excellent that these widely used and relatively safe drugs could be repurposed to treat breast cancer.
Program
Operating Grant - Priority Announcement: Breast Cancer
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
309700
Name
Hassell John A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Identification and characterization of drugs affecting serotonin signalling that may be repurposed to treat breast cancer
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Breast Cancer
Keyworddelim
Anticancer Drugs; Breast Cancer; Cancer Stem Cells; Pre-Clinical Animal Models
Abstract
We have discovered that drugs commonly used to treat patients suffering from depression, anxiety or migraine headaches, block the growth of breast tumour cells. These drugs, which include Prozac, Paxil and Zoloft, affect serotonin levels in particular neurons in the brain that control mood. Of relevance to this proposal, studies have shown that serotonin acts in women after breastfeeding is halted, by ridding the breast of cells that secrete milk proteins, a process termed involution. Interestingly the machinery needed to make and respond to serotonin is present in both milk-secreting normal breast cells as well as in breast tumour cells. Our interest in the role of serotonin in breast cancer resulted from a screen for drugs that kill breast tumour cells. We found that roughly 25% of the active drugs were psycho-stimulants and antidepressants that block the activity of various neurotransmitters, including serotonin. Follow-up experiments showed that these drugs killed a subset of breast tumour cells, termed cancer stem cells or breast tumour initiating cells, which have been implicated in sustaining tumour growth, seeding metastases and providing resistance to anticancer therapies. We have accumulated a significant body of data demonstrating that drugs inhibiting distinct serotonin pathway components all reduce the frequency of breast cancer stem cells. Most, but not all, of our experiments employed tumour cells from mouse models of breast cancer. Our proposal centers on learning whether serotonergic drugs eradicate human breast cancer stem cells from breast tumours. The use of such drugs in combination with chemotherapy is predicted to lead to durable breast cancer remissions. Because many approved antidepressant drugs are chronically used to treat patients with mood disorders the prospects are excellent that these widely used and relatively safe drugs could be repurposed to treat breast cancer.
Competitiondate
201403
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hassell, John A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~